Athenex announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company’s common stock will trade on a split-adjusted basis. At the Company’s Special Meeting of Stockholders held on November 22, 2022, the Company’s stockholders approved a proposal to authorize a reverse stock split of the Company’s common stock, at a ratio within the range of 1-for-5 to 1-for-20, as determined by the Company’s Board of Directors. The Board of Directors approved a 1-for-20 reverse split ratio, and on February 13, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split effective as of February 15, 2023. The Company’s Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Global Select Market.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATNX:
- Athenex Announces a Reverse Stock Split
- Athenex’s oral paclitaxel did not receive regulatory approval from U.K. MHRA
- Biotech Alert: Searches spiking for these stocks today
- Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
- Athenex says Quantum Leap reports results for I-SPY2 trial